DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

A Duchon, Y Herault - Frontiers in behavioral neuroscience, 2016 - frontiersin.org
Down syndrome (DS) is one of the leading causes of intellectual disability, and patients with
DS face various health issues, including learning and memory deficits, congenital heart …

Rodent models in Down syndrome research: impact and future opportunities

Y Herault, JM Delabar, EMC Fisher… - Disease models & …, 2017 - journals.biologists.com
Down syndrome is caused by trisomy of chromosome 21. To date, a multiplicity of mouse
models with Down-syndrome-related features has been developed to understand this …

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo …

R de la Torre, S de Sola, G Hernandez, M Farré… - The Lancet …, 2016 - thelancet.com
Background Early cognitive intervention is the only routine therapeutic approach used for
amelioration of intellectual deficits in individuals with Down's syndrome, but its effects are …

Timing of therapies for Down syndrome: the sooner, the better

F Stagni, A Giacomini, S Guidi, E Ciani… - Frontiers in behavioral …, 2015 - frontiersin.org
Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy
impact on public health. Accumulating evidence shows that DS is characterized by …

Down syndrome: Neurobiological alterations and therapeutic targets

RA Vacca, S Bawari, D Valenti, D Tewari… - Neuroscience & …, 2019 - Elsevier
Down syndrome (DS) is a genetic disease that occurs due to an aneuploidy of human
chromosome 21. Trisomy of chromosome 21 is a primary genetic cause of developmental …

Enriched environment-induced neuroplasticity in ischemic stroke and its underlying mechanisms

PP Han, Y Han, XY Shen, ZK Gao, X Bi - Frontiers in cellular …, 2023 - frontiersin.org
Stroke is a common cerebrovascular disease that can interrupt local blood flow in the brain,
causing neuronal damage or even death, resulting in varying degrees of neurological …

DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome

A Feki, Y Hibaoui - Brain sciences, 2018 - mdpi.com
Down syndrome (DS) caused by a trisomy of chromosome 21 (HSA21), is the most common
genetic developmental disorder, with an incidence of 1 in 800 live births. Its phenotypic …

[HTML][HTML] Harmine stimulates proliferation of human neural progenitors

V Dakic, R de Moraes Maciel, H Drummond… - PeerJ, 2016 - peerj.com
Harmine is the β-carboline alkaloid with the highest concentration in the psychotropic plant
decoction Ayahuasca. In rodents, classical antidepressants reverse the symptoms of …

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

TL Nguyen, A Duchon… - Disease models & …, 2018 - journals.biologists.com
Growing evidence supports the implication of DYRK1A in the development of cognitive
deficits seen in Down syndrome (DS) and Alzheimer's disease (AD). We here demonstrate …

Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach

Y Abukhaled, K Hatab, M Awadhalla, H Hamdan - Journal of Neurology, 2024 - Springer
The most common genetic cause of intellectual disability is Down syndrome (DS), trisomy
21. It commonly results from three copies of human chromosome 21 (HC21). There are no …